Filter Results:
(518)
Show Results For
- All HBS Web
(1,287)
- Faculty Publications (518)
Show Results For
- All HBS Web
(1,287)
- Faculty Publications (518)
- October 2014 (Revised May 2017)
- Teaching Note
Pfizer and AstraZeneca: Marketing an Acquisition (A) & (B)
By: John A. Quelch
- September 2014
- Supplement
Pfizer and AstraZeneca: Marketing an Acquisition (B)
By: John A. Quelch and James Weber
This (B) case provides a brief description of the outcome of the (A) case. View Details
Keywords: Health Care Policy; Pharmaceutical Sales; Mergers And Acquisitions; Marketing; Pharmaceutical Industry; United Kingdom; United States
Quelch, John A., and James Weber. "Pfizer and AstraZeneca: Marketing an Acquisition (B)." Harvard Business School Supplement 515-008, September 2014.
- September 2014 (Revised February 2015)
- Case
Pfizer and AstraZeneca: Marketing an Acquisition (A)
By: John A. Quelch and James Weber
In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details
Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States
Quelch, John A., and James Weber. "Pfizer and AstraZeneca: Marketing an Acquisition (A)." Harvard Business School Case 515-007, September 2014. (Revised February 2015.)
- September 2014
- Case
Pfizer's Centers for Therapeutic Innovation (CTI)
By: Gary Pisano, James Weber and Kait Szydlowski
In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration... View Details
Keywords: Drug Development; Academic Collaboration; Research And Development; Innovation; Translational Research; Management; Operations; Problems and Challenges; Research; Science; Information Technology; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; North and Central America; Europe; Asia
Pisano, Gary, James Weber, and Kait Szydlowski. "Pfizer's Centers for Therapeutic Innovation (CTI)." Harvard Business School Case 615-024, September 2014.
- July 2014 (Revised February 2015)
- Teaching Note
Johnson & Johnson: The Promotion of Wellness
By: John A. Quelch
The chief medical officer of Johnson & Johnson (J & J) is reflecting on forty years of sustained efforts by the company to improve employee wellness. The case reviews J & J's multiple wellness initiatives and efforts to measure their effectiveness. It also invites... View Details
Keywords: Empoylee Wellness Programs; Human Resource Management; Corporate Management Strategy; Employee Engagement; Human Resources; Management; Organizations; Performance; Personal Development and Career; Programs; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; North and Central America; Europe; Asia
- July 2014
- Teaching Note
Vaxess Technologies, Inc.
By: John A. Quelch
- June 2014
- Supplement
Merrimack Pharmaceuticals, Inc. (B)
By: Amy C. Edmondson, Bethany Gerstein and Melissa Valentine
In 2006, the leadership team at Merrimack Pharmaceuticals, Inc. had to decide whether to keep its R&D organization in functional departments or restructure it into interdisciplinary teams. This case follows the outcomes of this decision from 2006 to mid-2014, and... View Details
Keywords: Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Edmondson, Amy C., Bethany Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 614-083, June 2014.
- June 2014 (Revised February 2017)
- Case
Kathy Giusti and the Multiple Myeloma Research Foundation
By: Richard G. Hamermesh, Joshua D. Margolis and Matthew G. Preble
What do you do when your rising professional career is cut short by an unexpected cancer diagnosis? Kathy Giusti shifted careers, built a new organization that transformed how cancer research is done, and now faces the challenge of sustaining the organization and its... View Details
Keywords: Philanthropy; Philanthropy Funding; Entrepreneurship; Health Care; Management Styles; Personalized Medicine; Health Care Outcomes; Cancer; Cancer Care In The U.S.; Personal Care; Leadership; Leading Change; Social Entrepreneurship; Philanthropy and Charitable Giving; Health Care and Treatment; Leadership Style; Management Style; Management Skills; Growth and Development Strategy; Business Strategy; Health; Health Industry; United States; Canada; Spain
Hamermesh, Richard G., Joshua D. Margolis, and Matthew G. Preble. "Kathy Giusti and the Multiple Myeloma Research Foundation." Harvard Business School Case 814-026, June 2014. (Revised February 2017.)
- June 2014 (Revised September 2014)
- Case
Johnson & Johnson: The Promotion of Wellness
By: John A. Quelch and Carin-Isabel Knoop
To create the world's healthiest workforce, diversified health care giant Johnson & Johnson (J&J) mandated participation in its "Culture of Health" program globally, customized by location, culture, and specific health needs to offer prevention-focused education,... View Details
Keywords: Healthcare; Employee Motivation; Transformation; Ethics; Health; Human Resources; Leadership; Management; Personal Development and Career; Problems and Challenges; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; North and Central America; Middle East; Latin America; Europe; Asia
Quelch, John A., and Carin-Isabel Knoop. "Johnson & Johnson: The Promotion of Wellness." Harvard Business School Case 514-112, June 2014. (Revised September 2014.)
- June 2014 (Revised May 2017)
- Teaching Note
Vision 2020: Takeda and the Vaccine Business
By: John A. Quelch
- May 2014
- Article
Right Up the Middle: How Israeli Firms Go Global
By: Jonathan Friedrich, Amit Noam and Elie Ofek
The article considers international business enterprises based in Israel and how they successfully expanded from their origins as small businesses. A common technique of those companies in which they focused on market entry in other countries whose markets were too... View Details
Friedrich, Jonathan, Amit Noam, and Elie Ofek. "Right Up the Middle: How Israeli Firms Go Global." Harvard Business Review 92, no. 5 (May 2014): 113–117.
- April 2014 (Revised July 2015)
- Case
Sanofi Pasteur: The Dengue Vaccine Dilemma
By: V. Kasturi Rangan, David E. Bloom, Vincent Dessain and Emilie Billaud
In 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a... View Details
Keywords: Health Testing and Trials; Product Launch; Market Entry and Exit; Emerging Markets; Pharmaceutical Industry; France
Rangan, V. Kasturi, David E. Bloom, Vincent Dessain, and Emilie Billaud. "Sanofi Pasteur: The Dengue Vaccine Dilemma." Harvard Business School Case 514-074, April 2014. (Revised July 2015.)
- April 2014
- Case
Merrimack Pharmaceuticals, Inc. (A)
By: Amy C. Edmondson, Bethany S. Gerstein and Melissa Valentine
In 2006, Merrimack Pharmaceuticals was a fast-growing biotechnology company. Its leadership team was divided over whether to keep R&D organized in functional departments or transition to interdisciplinary teams. As a small company, Merrimack's R&D organization had... View Details
Keywords: Teamwork; Interdisciplinary Collaboration; R&D; Biotechnology; Complexity; Innovation Management; Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Edmondson, Amy C., Bethany S. Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (A)." Harvard Business School Case 614-063, April 2014.
- 2014
- Working Paper
The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories
By: Francesca Lazzeri and Gary P. Pisano
Scholars and practitioners alike now recognize that a firm's capacity to assimilate and use know-how from external sources—what Cohen and Levinthal (1990) called "absorptive capacity"—plays a central role in innovation performance. In recent years, a common strategy... View Details
Keywords: Geographic Location; Industry Clusters; Knowledge Acquisition; Pharmaceutical Industry; San Francisco; San Diego; Massachusetts
Lazzeri, Francesca, and Gary P. Pisano. "The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories." Harvard Business School Working Paper, No. 14-098, April 2014.
- Spring 2014
- Article
Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company
By: Andrew Knauer and George Serafeim
Faced with a large percentage of investors that chase short-term returns, companies could benefit by attracting investors with longer-term horizons and incentives that are more consistent with the long-term strategy of the company. The managers of most companies take... View Details
Keywords: Investing; Asset Management; Long-term Investing; Short-termism; Sustainability; Integrated Reporting; Leadership & Corporate Accountability; Pharmaceuticals; Leadership; Integrated Corporate Reporting; Investment; Business and Stakeholder Relations; Corporate Finance; Pharmaceutical Industry; Pharmaceutical Industry
Knauer, Andrew, and George Serafeim. "Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company." Journal of Applied Corporate Finance 26, no. 2 (Spring 2014): 57–64.
- March 2014 (Revised December 2014)
- Case
Vision 2020: Takeda and the Vaccine Business
By: John A. Quelch and Margaret L. Rodriguez
In 2014, Yasuchika Hasegawa was orchestrating the transformation of Takeda from a Japanese pharmaceutical company with a global footprint into a global company with a Japanese heritage. A 33-year veteran of Takeda, Hasegawa-san was appointed president of Takeda in 2003... View Details
Keywords: Health Care; Global; NGO; Public Health; Japan; GSK; Vaccine; Supply Chain; Market Entry; Health; Health Care and Treatment; Trade; Market Entry and Exit; Global Strategy; Pharmaceutical Industry; Pharmaceutical Industry
Quelch, John A., and Margaret L. Rodriguez. "Vision 2020: Takeda and the Vaccine Business." Harvard Business School Case 514-084, March 2014. (Revised December 2014.)
- March 2014
- Case
Novartis' Sandoz: Between Generics and Pharma
By: Krishna Palepu and Carin-Isabel Knoop
Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What... View Details
Keywords: Global Strategy And Leadership; Managing Within A Multi-Business Organization; Generic Pharmaceuticals; Global Strategy
Palepu, Krishna, and Carin-Isabel Knoop. "Novartis' Sandoz: Between Generics and Pharma." Harvard Business School Case 114-033, March 2014.
- 2014
- Working Paper
Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms
By: Prithwiraj Choudhury and Tarun Khanna
Since the 1990s, several Western firms have filed patents based on medicinal herbs from emerging markets, evoking protests from local stakeholders against 'bio-piracy'. We explore conditions under which firms and local stakeholders share rents from such patents. Our... View Details
Keywords: Rents From New Technology; Local Stakeholders; Herbal Patents; QCA; Fuzzy Set Analysis; Qualitative Case Studies; Plant-Based Agribusiness; Patents; Emerging Markets; Health Care and Treatment; Business and Stakeholder Relations; Cross-Cultural and Cross-Border Issues; Pharmaceutical Industry; Pharmaceutical Industry
Choudhury, Prithwiraj, and Tarun Khanna. "Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms." Harvard Business School Working Paper, No. 14-081, February 2014.
- 2018
- Working Paper
Information Provision and Innovation: Natural Experiment of Herbal Patent Prior Art Adoption at the United States and European Patent Offices
By: Prithwiraj Choudhury and Tarun Khanna
We exploit a natural experiment to study how codifying information about prior innovation affects subsequent innovation. A codified database of traditional Indian herbal formulations was adopted by the European Patent Office (EPO) and the U.S. Patent and Trademark... View Details
Keywords: Patents; Plant-Based Agribusiness; Ethnicity; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; China; India
Choudhury, Prithwiraj, and Tarun Khanna. "Information Provision and Innovation: Natural Experiment of Herbal Patent Prior Art Adoption at the United States and European Patent Offices." Harvard Business School Working Paper, No. 14-079, February 2014. (Revised January 2018.)
- January 2014 (Revised January 2014)
- Supplement
GlaxoSmithKline in China (C)
By: John Quelch and Margaret L. Rodriguez
Keywords: China; Healthcare; Pharmaceutical Sales; Ethics; Multinational Firms and Management; Pharmaceutical Industry; China
Quelch, John, and Margaret L. Rodriguez. "GlaxoSmithKline in China (C)." Harvard Business School Supplement 514-092, January 2014. (Revised January 2014.) (This case is a follow up to GlaxoSmithKline (A), 514049 and GlaxoSmithKline (B), 514050.)